Truist raised the firm’s price target on Tenet Healthcare to $84 from $74 and keeps a Buy rating on the shares. The company’s Q1 results were better than expected across segments, driven by brisk volume trends and ongoing labor recovery, the analyst tells investors in a research note. Truist adds that Tenet’s improved balance sheet optionality should help underpin the company’s ongoing growth investment.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on THC:
- Tenet Healthcare price target raised to $84 from $73 at RBC Capital
- Tenet Healthcare price target raised to $105 from $70 at Barclays
- Tenet Healthcare sees FY23 adjusted EPS $4.92-$6.09
- Tenet Healthcare reports Q1 adjusted EPS $1.42 vs. $1.90 last year
- HCA Healthcare price target raised to $323 from $294 at BofA